drugset / Trial / NCT05561374
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.
Timeline
- Start
- 2023-04-17
- Primary completion
- 2025-05-31
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DISUFENTON | Small molecule | — | Oral |